Top 10 Life Science Angel Investors in France in May 2026

Portfolio highlights

• GOURMEY — We create sustainable cultivated meat delights for an uncompromising and conscious generation.
• Waldo — The codeless way to quickly build a comprehensive test suite for teams who don't compromise on speed and quality.
• TOTEM — A Totem is a place of sharing and conviviality in your office. This is an opportunity for your colleagues to get to know each other better, celebrate victories and defeats together, and build a solid culture.

Portfolio highlights

• Yavin — Yavin provides modern point-of-sale solutions for European merchants
• Jump — Jump takes the hassle out of being a freelancer. We accompany hundreds of freelancers in their daily lives by securing their adventure. Relax, we take care of everything.
• Core Biogenesis — Biodesigning the Future of Regenerative Medicine & Skincare

Portfolio highlights

• Jop — A one-stop-shop for urban residents, Jop offers a variety of on-demand services in one convenient, easy-to-use platform. Customers can tap a screen and connect with a professional in their city, whether they are an expert at cleaning apartments, trimming mustaches, walking dogs, doing makeup, DJing, or mixing drinks. Instead of paying a company’soverhead, customers pay a Jopper. Once booked, Joppers arrive right at the customer’s doorstep, ready to work.Founded by Canel Frichet and Sebastian Lombardo, Jop was born as a platform to give people the opportunity to work directly for each other, as opposed to hiring through a company. Joppers set their own pricing and hours. Something else that sets JOP apart from other platforms in the on-demand space is that Joppers earn company equity, which is granted based on level of activity and performance on the platform.
• Smart Immune — Smart Immune is a clinical-stage biotechnology company focused on developing the next generation of hematopoietic stem cell-based biotherapies to change the prognosis and life quality of patients with devastating diseases. The company's first cell therapy program is based on T cell progenitors or ProTcellsTM (CD7+/CD34-; CD5- cells)curative power to enable a short, polyclonal, and safe post-transplantation immune recovery. This program be completed by integrative developments from targeted conditioning to gene therapy and genome editing enabling clinicians to access new-generation treatments for a wide variety of inherited blood disorders and blood cancers.

Portfolio highlights

• Somite — Somite.ai is on a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies.
• Owner — Owner gives you the same tools that major national brands use to drive sales. Online ordering proven to grow sales. Mobile app with rewards. And more.
• Breezy — Breezy is a mobile-first AI workspace for real estate agents that provides virtual assistant services and CRM systems for realtors and brokerages.

Portfolio highlights

• Okomera — Automated 3D model drug testing of cancer biopsies prior to treatment. For precision and personalized medicine. The "test before you treat" solution for every oncologist and patient.
• Lutra AI — Lutra AI is to simplify complex tasks that specializes in workflows, created by the platform.
• Twin — Twin Labs, offer an automated tool for repetitive operations, such as onboarding new staff to all internal systems.

Portfolio highlights

• Gradium — Gradium.ai provides audio language models that enable natural, expressive, ultra-low latency voice interactions at scale, unifying speech generation, transcription, voice transformation, and dialogue in a single neural architecture.The platform acts as an audio-native counterpart to text-based large language models, processing tasks like real-timespeech-to-speech with delays under 200 milliseconds through optimized architectures, efficient tokenization, and hardware-aware deployments. It supports multilingual capabilities in English, French, German, Spanish, and Portuguese, with plans for expansion.
• Genesis AI — Genesis AI operates as a physical AI lab and full-stack robotics company.
• Cube AI — Cube AI provides software that applies machine learning to business workflows and data. The platform enables creation of AI assistants, connections to internal data sources, and task automation through APIs and integrations. Capabilities include natural language processing for classification, summarization, and question answering, retrieval overdocuments and knowledge bases, and analytics that surface insights from structured and unstructured data. Solutions cover use cases such as customer support, sales enablement, lead routing, and document processing, helping teams reduce manual steps and standardize processes. Tooling includes SDKs, dashboards, and monitoring to deploy, observe, and refine models in production.

Portfolio highlights

• reMYND — Driving the development of disease-modifying treatments
• AgenT — AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms.
• PEP-Therapy — PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology

Portfolio highlights

• Bolk — Bolk provides autonomous bowl-making robotic canteen which producing warm meals, cold dishes and desserts from precooked ingredients.
• Arkania — B2B API solution for brands to create and sell online NFTs directly on their platforms
• Starton — Integrate blockchain technology this week. Focus on your vision, we handle blockchain complexity

Portfolio highlights

• Cytoo — Pioneering muscle pathology research with our exclusive MyoScreen platform to accelerate drug target identification and therapeutic innovation.
• Okomera — Automated 3D model drug testing of cancer biopsies prior to treatment. For precision and personalized medicine. The "test before you treat" solution for every oncologist and patient.

Portfolio highlights

• Antabio — Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. Thecompany's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.